Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097969 | 0.97 | CYP2D6 (0.64) | CYP2D6POLBCD274PDK2MEN1 | |
| SCHEMBL13097784 | 0.83 | CYP2D6 (0.60) | CYP2D6MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13097579 | 0.82 | CYP2D6 (0.67) | CYP2D6KDM4EALDH1A1 | |
| SCHEMBL13097787 | 0.81 | CYP2D6 (0.59) | CYP2D6KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL13097795 | 0.80 | CYP2D6 (0.58) | CYP2D6KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL13097528 | 0.80 | CYP2D6 (1.00) | CYP2D6KDM4EALDH1A1 | |
| SCHEMBL13097624 | 0.78 | CYP2D6 (0.64) | CYP2D6MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13097572 | 0.77 | CYP2D6 (0.75) | CYP2D6 | |
| SCHEMBL13097972 | 0.77 | CYP2D6 (0.68) | CYP2D6POLBMEN1KMT2AKDM4E | |
| SCHEMBL13097686 | 0.77 | CYP2D6 (0.68) | CYP2D6POLBMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885POLB 1824/4885CD274 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.